Piper Sandler Downgrades American Well to Neutral, Lowers Price Target to $3.5
Piper Sandler analyst Jessica Tassan downgrades American Well (NYSE:AMWL) from Overweight to Neutral and lowers the price target from $5 to $3.5.
Cantor Fitzgerald Downgrades Sono Group to Neutral, Lowers Price Target to $1
Cantor Fitzgerald analyst Andres Sheppard downgrades Sono Group (NASDAQ:SEV) from Overweight to Neutral and lowers the price target from $3 to $1.
Raymond James Downgrades Limestone Bancorp to Market Perform
Raymond James analyst Daniel Tamayo downgrades Limestone Bancorp (NASDAQ:LMST) from Outperform to Market Perform.
Piper Sandler Downgrades CS Disco to Neutral, Lowers Price Target to $7.5
Piper Sandler analyst Arvind Ramnani downgrades CS Disco (NYSE:LAW) from Overweight to Neutral and lowers the price target from $11 to $7.5.
SMBC Nikko Downgrades Jounce Therapeutics to Neutral
SMBC Nikko analyst David Dai downgrades Jounce Therapeutics (NASDAQ:JNCE) from Outperform to Neutral.
Baird Downgrades Domino’s Pizza to Neutral, Lowers Price Target to $320
Baird analyst David Tarantino downgrades Domino's Pizza (NYSE:DPZ) from Outperform to Neutral and lowers the price target from $400 to $320.
Cantor Fitzgerald Downgrades Root to Neutral, Lowers Price Target to $6
Cantor Fitzgerald analyst Josh Siegler downgrades Root (NASDAQ:ROOT) from Overweight to Neutral and lowers the price target from $22 to $6.
Deutsche Bank Downgrades Venator Materials to Hold, Lowers Price Target to $0.5
Deutsche Bank analyst David Begleiter downgrades Venator Materials (NYSE:VNTR) from Buy to Hold and lowers the price target from $1 to $0.5.
Jefferies Downgrades Nektar Therapeutics to Underperform, Lowers Price Target to $1.5
Jefferies analyst Roger Song downgrades Nektar Therapeutics (NASDAQ:NKTR) from Hold to Underperform and lowers the price target from $3.2 to $1.5.
JP Morgan Downgrades C4 Therapeutics to Underweight, Lowers Price Target to $5
JP Morgan analyst Eric Joseph downgrades C4 Therapeutics (NASDAQ:CCCC) from Neutral to Underweight and lowers the price target from $15 to $5.